• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用分段回归分析研究铜绿假单胞菌的抗菌药物利用和耐药性：塞尔维亚与 8 个欧洲国家的比较研究。

Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries.

机构信息

Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, Serbia.

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.

出版信息

Int J Clin Pharm. 2023 Aug;45(4):989-998. doi: 10.1007/s11096-023-01603-y. Epub 2023 Jun 7.

DOI:10.1007/s11096-023-01603-y
PMID:37284904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10246517/
Abstract

BACKGROUND

In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR).

AIM

The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006-2020), and the reported AMR in Pseudomonas aeruginosa (2013-2020) in Serbia and to compare with data from eight European countries (2015-2020).

METHOD

Joinpoint regression was used to analyse antibiotic utilization data (2006-2020) and the reported AMR in Pseudomonas aeruginosa (2013-2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries.

RESULTS

There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aeruginosa, Serbia (p < 0.05) (2018-2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseudomonas aeruginosa an increased trend was observed, Serbia (2013-2020). A decrease in both the utilization of aminoglycosides, Serbia (p < 0.05) (2006-2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015-2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015-2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015-2020).

CONCLUSION

The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.

摘要

背景

在欧洲，塞尔维亚的抗生素利用和抗菌药物耐药性（AMR）水平较高。

目的

分析 2006 年至 2020 年期间，美罗培南、头孢他啶、氨基糖苷类、哌拉西林/他唑巴坦和氟喹诺酮类药物的利用趋势，以及 2013 年至 2020 年期间，铜绿假单胞菌的报告 AMR，并与 8 个欧洲国家（2015 年至 2020 年）的数据进行比较。

方法

采用 Joinpoint 回归分析 2006 年至 2020 年抗生素利用数据和 2013 年至 2020 年铜绿假单胞菌报告的 AMR。数据来源为相关国家和国际机构。比较塞尔维亚与 8 个欧洲国家的抗生素利用和铜绿假单胞菌 AMR 数据。

结果

塞尔维亚头孢他啶利用和铜绿假单胞菌耐药率呈显著上升趋势（p<0.05）（2018-2020 年）。头孢他啶、哌拉西林/他唑巴坦和氟喹诺酮类药物对铜绿假单胞菌的耐药性呈上升趋势，塞尔维亚（2013-2020 年）。同时，塞尔维亚氨基糖苷类药物的利用（p<0.05）（2006-2018 年）和铜绿假单胞菌耐药率（p>0.05）均呈下降趋势。与荷兰和芬兰相比，塞尔维亚氟喹诺酮类药物的利用（2015-2020 年）分别高出 310%和 305%，与罗马尼亚相似，比黑山低 2%。与芬兰和荷兰相比，塞尔维亚氨基糖苷类药物的利用（2015-2020 年）分别高出 2550%和 783%，而与黑山相比则低 38%。2015-2020 年，罗马尼亚和塞尔维亚铜绿假单胞菌耐药率最高。

结论

由于铜绿假单胞菌耐药性增加，应谨慎监测哌拉西林/他唑巴坦、头孢他啶和氟喹诺酮类药物的临床应用。与其他欧洲国家相比，塞尔维亚的铜绿假单胞菌的利用和 AMR 水平仍然较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/0864582dcecd/11096_2023_1603_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/ec50b675ba02/11096_2023_1603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/c25c971a579b/11096_2023_1603_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/92d2af4916cc/11096_2023_1603_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/ad651382eabb/11096_2023_1603_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/0864582dcecd/11096_2023_1603_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/ec50b675ba02/11096_2023_1603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/c25c971a579b/11096_2023_1603_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/92d2af4916cc/11096_2023_1603_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/ad651382eabb/11096_2023_1603_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada2/10246517/0864582dcecd/11096_2023_1603_Fig5_HTML.jpg

相似文献

1
Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries.使用分段回归分析研究铜绿假单胞菌的抗菌药物利用和耐药性：塞尔维亚与 8 个欧洲国家的比较研究。
Int J Clin Pharm. 2023 Aug;45(4):989-998. doi: 10.1007/s11096-023-01603-y. Epub 2023 Jun 7.
2
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).广谱β-内酰胺类药物对铜绿假单胞菌活性的地理差异：全球SENTRY抗菌药物监测计划（1997 - 2000年）总结
Diagn Microbiol Infect Dis. 2002 Jul;43(3):239-43. doi: 10.1016/s0732-8893(02)00390-5.
3
Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.铜绿假单胞菌菌血症患者死亡的危险因素：抗菌药物耐药性对预后的临床影响。
Microb Drug Resist. 2011 Jun;17(2):305-12. doi: 10.1089/mdr.2010.0170. Epub 2011 Mar 7.
4
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
5
Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital.开发一种联合药敏谱，用于治疗大学附属医院的铜绿假单胞菌感染的经验性治疗。
J Microbiol Immunol Infect. 2023 Apr;56(2):344-350. doi: 10.1016/j.jmii.2022.08.012. Epub 2022 Sep 8.
6
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.头孢他啶、碳青霉烯类或哌拉西林他唑巴坦作为铜绿假单胞菌菌血症的单一确定性治疗：一项多中心回顾性研究。
Clin Infect Dis. 2020 May 23;70(11):2270-2280. doi: 10.1093/cid/ciz668.
7
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
8
Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa.评估多重耐药铜绿假单胞菌的共耐药率和患者结局。
Microbiol Spectr. 2022 Oct 26;10(5):e0233622. doi: 10.1128/spectrum.02336-22. Epub 2022 Aug 25.
9
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.头孢他洛滨他唑巴坦与传统β-内酰胺类药物的比较以及头孢他洛滨他唑巴坦作为铜绿假单胞菌联合抗菌治疗替代方案的比较。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
10
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.体外研究头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、美罗培南-沃巴坦和其他对照药物对碳青霉烯类药物耐药程度不一致的铜绿假单胞菌分离株的活性：来自抗菌药物检测领导和监测（ATLAS）计划的数据，2012-2021 年。
Int J Antimicrob Agents. 2023 Aug;62(2):106867. doi: 10.1016/j.ijantimicag.2023.106867. Epub 2023 May 25.

引用本文的文献

1
Antimicrobial Use and Awareness of Antimicrobial Resistance in the Livestock Sector in the Western Balkans.西巴尔干地区畜牧业中的抗菌药物使用及对抗菌药物耐药性的认知
Antibiotics (Basel). 2025 Aug 19;14(8):839. doi: 10.3390/antibiotics14080839.
2
Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective.揭示脓毒症的研究进展：发病机制、精准干预及临床展望
Int J Surg. 2025 Jun 23;111(9):6260-89. doi: 10.1097/JS9.0000000000002668.
3
Posttraumatic Osteomyelitis in Mosul and Gaza: A Retrospective Cohort Study, 2018-2022.

本文引用的文献

1
Impact of Antibiotic Consumption on Antimicrobial Resistance to Invasive Hospital Pathogens.抗生素使用对侵袭性医院病原体抗菌药物耐药性的影响。
Antibiotics (Basel). 2023 Jan 28;12(2):259. doi: 10.3390/antibiotics12020259.
2
Antibiotic (Mis)Use in COVID-19 Patients before and after Admission to a Tertiary Hospital in Serbia.塞尔维亚一家三级医院收治的新冠肺炎患者入院前后的抗生素（误）用情况
Antibiotics (Basel). 2022 Jun 24;11(7):847. doi: 10.3390/antibiotics11070847.
3
Increase and Change in the Pattern of Antibiotic Use in Serbia (2010-2019).
摩苏尔和加沙地区的创伤后骨髓炎：一项2018 - 2022年的回顾性队列研究
Open Forum Infect Dis. 2024 Oct 7;11(10):ofae579. doi: 10.1093/ofid/ofae579. eCollection 2024 Oct.
塞尔维亚抗生素使用模式的增加与变化（2010 - 2019年）
Antibiotics (Basel). 2021 Apr 7;10(4):397. doi: 10.3390/antibiotics10040397.
4
Decreasing and stabilising trends of antimicrobial consumption and resistance in and in segmented regression analysis, European Union/European Economic Area, 2001 to 2018.在分段回归分析中，2001 年至 2018 年，和 的抗菌药物消耗和耐药性呈下降和稳定趋势。
Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560-7917.ES.2019.24.46.1900656.
5
Antibiotic Prescribing and Respiratory Viral Testing for Acute Upper Respiratory Infections Among Adult Patients at an Ambulatory Cancer Center.门诊癌症中心成人急性上呼吸道感染患者的抗生素处方和呼吸道病毒检测。
Clin Infect Dis. 2020 Mar 17;70(7):1421-1428. doi: 10.1093/cid/ciz409.
6
A join point regression analysis of trends in mortality due to osteoporosis in Spain.对西班牙骨质疏松症死亡率趋势的连接点回归分析。
Sci Rep. 2019 Mar 12;9(1):4264. doi: 10.1038/s41598-019-40806-0.
7
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.2015 年欧盟及欧洲经济区因抗生素耐药菌感染导致的死亡人数和伤残调整生命年：基于人群的模型分析。
Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4. Epub 2018 Nov 5.
8
Predictors of self-medication in Serbian adult population: cross-sectional study.塞尔维亚成年人群自我药疗的预测因素：横断面研究。
Int J Clin Pharm. 2018 Jun;40(3):627-634. doi: 10.1007/s11096-018-0624-x. Epub 2018 Mar 30.
9
Previous Antibiotic Exposure and Antimicrobial Resistance Patterns of spp. and aeruginosa Isolated from Patients with Nosocomial Infections.先前抗生素暴露与医院感染患者分离的 spp. 和 aeruginosa 的抗微生物耐药模式。
Balkan Med J. 2017 Dec 1;34(6):527-533. doi: 10.4274/balkanmedj.2016.1844.
10
Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy.铜绿假单胞菌抗生素耐药性的流行病学。对经验性和确定性治疗的影响。
Rev Esp Quimioter. 2017 Sep;30 Suppl 1:8-12.